Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment

20 Jan 2021

Abstract excerpt

OBJECTIVE: To examine patient/caregiver preference for key attributes of treatments for spinal muscular atrophy (SMA). BACKGROUND: In the rapidly evolving SMA treatment landscape, it is critically important to understand how attributes of potential treatments may impact patient/caregiver choices. DESIGN/METHODS: A discrete choice experiment survey was developed based on qualitative interviews. Patients with SMA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Craniofacial Disorders and Treatments
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33472673
DOI: 10.1186/s13023-020-01667-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experimentPMID 33472673Read ↗

Preferences for genetic interventions for SCA and Huntington’s disease: results of a discrete choice experiment among patients.Semantic proximity Read ↗

Is it ethical to reimburse “SMA Innovative Treatments” from government resources?Semantic proximity Read ↗

A qualitative, mixed-method approach to reaching consensus on function, fatigue, and fatigability outcomes in teens and adults living with spinal muscular atrophySemantic proximity Read ↗

Gene-Based Therapy for the Treatment of Spinal Muscular Atrophy Types 1 and 2 : A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesSemantic proximity Read ↗

Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.Semantic proximity Read ↗

PREFER-DMT: A Discrete Choice Experiment Framework for Eliciting Stakeholder Preferences on Disease-Modifying Therapy Implementation in European Healthcare SystemsSemantic proximity Read ↗

Caregiver Perspectives on Patients with Mucopolysaccharidosis II Treated with Pabinafusp Alfa: Results of Qualitative Interviews in JapanSemantic proximity Read ↗

Twelve-Month Outcomes of Intrathecal Vesemnogene Lantuparvovec for Spinal Muscular Atrophy in Children Younger than 24 Months in Low- and Middle-Income CountriesSemantic proximity Read ↗

Spinal Muscular Atrophy: The High Costs of Innovative Therapies for Rare DiseasesSemantic proximity Read ↗

Patients' Preferences for Attributes of Molecular Targeting Therapies for Advanced Non-Small Cell Lung Cancer with EGFR Mutations in Japan-A Discrete-Choice Experiment.Semantic proximity Read ↗

Public Preferences for Digital Therapies in Alzheimer's Disease Treatment: A Discrete Choice Experiment in ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.